Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Charlottesville, Virginia 22903


Arterial vascular disease is the major cause of morbidity and mortality for Type 1 diabetic patients (DM1). Metabolic insulin resistance (metIR), even in the absence of hyperglycemia, conveys a 1.5 to 3-fold increased CVD risk in the general population. Metabolic Insulin Resistance (MetIR) has been repeatedly shown to be prevalent in adults and adolescents with DM1. MetIR in obesity and DM2 are accompanied by vascular insulin resistance (vasIR) which is characterized by impaired vasodilatory action of insulin on resistance or microvascular vessels. VasIR has not been systematically studied in DM1. We hypothesize that in young adults DM1 impairs both baseline and insulin-responsive vascular function throughout the arterial vasculature.

Study summary:

In our study, 20 healthy control subjects will be compared to 20 DM1 patients (18-40 yrs). We will assess function in conduit (pulse wave velocity-PWV, flow-mediated dilation-FMD and augmentation index-AI), resistance (post-ischemic flow velocity-PIFV) and heart and skeletal muscle microvascular (contrast enhanced ultrasound-CEU) vessels before and after 2 hrs of a euglycemic insulin clamp.


Inclusion Criteria: - Age 18-40 - BMI ≤ 25 - Healthy with no chronic illness (control group only) - Normal screening labs or no clinically significant values - DM1 subjects will have been on insulin for at least 5 years and HbA1c <9 Exclusion Criteria: - First degree relative with Type 1 or 2 Diabetes (for control group only) - Smoking presently or in the past 6 months - Medications that affect the vasculature (except ACE or ARB in DM1 subjects, although they will need to be off these drugs for 2 weeks prior to study). - Elevated LDL cholesterol > 160 - BP <100/60 or >160/90 - Pulse oximetry <90% - Pregnant or breastfeeding - History of cardiovascular disease, cerebral vascular disease, peripheral vascular disease, liver disease - Presence of an intracardiac or intrapulmonary shunt (we will screen for this by auscultation during the physical exam ). - Known hypersensitivity to perflutren (contained in Definity) - For DM1 group: - HbA1c ≥ 9 - Microalbuminuria - Retinipathy - Ketoacidosis within the past year.



Primary Contact:

Principal Investigator
Eugene J. B, MD, PhD
University of Virginia

Backup Contact:


Location Contact:

Charlottesville, Virginia 22903
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: January 21, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.